<DOC>
	<DOCNO>NCT00731731</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose vorinostat give together temozolomide radiation therapy see well work treat patient newly diagnose glioblastoma multiforme . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving vorinostat together temozolomide radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) vorinostat patient newly diagnose glioblastoma multiforme ( GBM ) gliosarcomas , also receive concomitant radiation therapy ( RT ) temozolomide ( TMZ ) . ( Phase I ) II . To define safety vorinostat RT TMZ population . ( Phase II ) III . To determine efficacy vorinostat combination RT TMZ follow vorinostat combination TMZ patient newly-diagnosed GBM gliosarcomas measure overall survival 15 month ( OS15 ) . ( Phase II ) SECONDARY OBJECTIVES : I . To determine progression-free survival newly diagnose GBM gliosarcoma patient treat study regimen . ( Phase II ) II . To evaluate safety profile vorinostat combination RT TMZ patient population . ( Phase II ) III . Determine neurocognitive effect patient treat protocol correlate result outcome endpoint . ( Phase II ) TERTIARY OBJECTIVES : I . To explore extent tumor 's molecular characteristic expression profile correlate outcome . II . Evaluate potential mechanism therapy resistance tumor sample obtain time tumor progression . OUTLINE : This phase I , dose-escalation study vorinostat follow phase II study . Patients undergo radiotherapy receive vorinostat orally ( PO ) daily ( QD ) day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Patients also receive temozolomide PO QD day 1-42 . Beginning 4-6 week later , patient receive vorinostat PO QD day 1-7 15-21 temozolomide PO QD day 1-5 . Treatment vorinostat temozolomide repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month 1 year , every 3 month 1 year every 6 month 3 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>PREREGISTRATION : Central pathology review submission ; review mandatory prior registration confirm eligibility ; initiate soon surgery possible Treatment begin &gt; = 2 week = &lt; 5 week follow surgery REGISTRATION : Histologically confirm glioblastoma multiforme determine preregistration central pathology review ; Note : gliosarcomas grade 4 astrocytoma variant ( e.g. , giant cell ) eligible Measurable evaluable disease gadolinium magnetic resonance imaging ( MRI ) contrast compute tomography ( CT ) scan ; Note : patient gross total resection ( GTR ) eligible basis evaluable disease Must begin partial brain radiotherapy day vorinostat temozolomide begin Karnofsky performance status &gt; = 60 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 White blood cell ( WBC ) &gt; = 3,000/mm^3 Hemoglobin &gt; = 10.0 g/dL ; Note : level may reach transfusion Total bilirubin = &lt; 2.0 x institutional upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 2.0 x ULN Creatinine = &lt; 1.5 mg/dL Life expectancy &gt; = 12 week Negative serum pregnancy test do = &lt; 7 day prior registration , woman childbearing potential For Phase I establish MTD Phase II patient : Willing able complete neurocognitive test Ability provide inform write consent Willing return Alliance Adult Brain Tumor Consortium ( ABTC ) enrol institution followup Phase I establish MTD patient Phase II patient : Willing provide mandatory tissue sample ( slide block ) research purpose Willing forego cytotoxic noncytotoxic drug therapy tumor treat vorinostat temozolomide Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception throughout duration study 12 week treatment end Prior cytotoxic drug therapy , noncytotoxic drug therapy , experimental drug therapy brain tumor Prior cranial RT Prior Gliadel wafer Known hypersensitivity component vorinostat agent use study Valproic acid , another histone deacetylase inhibitor , = &lt; 2 week prior registration treatment Other active malignancy = &lt; 3 year prior registration ; Exception : nonmelanotic skin cancer carcinoma situ cervix ; Note : history prior malignancy , must receive specific treatment ( hormonal therapy ) cancer Uncontrolled infection Immunocompromised patient patient know human immunodeficiency virus ( HIV ) positive currently receive antiretroviral therapy ; Note : patient know HIV positive , without clinical evidence immunocompromised state , eligible trial Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety adverse event prescribe regimen Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement History myocardial infarction unstable angina = &lt; 6 month prior registration congestive heart failure ( CHF ) require use ongoing maintenance therapy lifethreatening ventricular arrhythmias New York Heart Association ( NYHA ) &gt; = Class II Congestive Heart Failure Inability take oral medication Receiving investigational agent would consider treatment primary neoplasm Congenital long QT syndrome Prolonged correct ( QTc ) interval ( &gt; 450 msec ) Any follow Category I drug generally accept risk cause Torsades de Pointes = &lt; 7 day prior registration Quinidine , procainamide , disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin , clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide Cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>